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ide QRS, Narrow QRS
hat’s the Difference?*
rian Olshansky, MD, FACC†
owa City, Iowa
mplantable cardioverter-defibrillators (ICDs) reduce the
isk of death in properly selected patients. The Combined
edicare and Medicaid Services (CMS) had recommended
rophylactic ICDs only for those patients with ischemic
eart disease, a left ventricular ejection fraction 0.30, and
QRS width 120 ms (1). The QRS duration was
herefore a concern.
Based on a retrospective analysis of the patients with
CDs enrolled in the PainFREE Rx II trial (2), Buxton et
l. in this issue of the Journal (3) report that QRS width
oes not predict ventricular tachycardia (VT) and ventricu-
ar fibrillation (VF) events. The QRS duration did predict
ortality (9% for QRS 120 ms vs. 15% for QRS 120
s, p  0.047). These intriguing data deserve a closer look.
See page 310
RS WIDTH PREDICTS SURVIVAL, BUT ARE ALL
IDE QRS COMPLEXES THE SAME?
ll interventricular conduction delays do not necessarily
ave the same prognostic value. The QRS duration predicts
urvival in patients with heart failure who have a left bundle
ranch block (LBBB) (4) and when the QRS is exceedingly
ide (5,6) regardless of the presence or absence of coronary
rtery disease (4,7).
A registry of 5,517 patients (46% with ischemic heart
isease) showed that LBBB and survival were associated in
atients with heart failure. The LBBB was associated with
n increased total mortality from any cause (hazard ratio
HR] 1.70, 95% confidence interval [CI] 1.41 to 2.05) and
udden death (HR 1.58, 95% CI 1.21 to 2.06) independent
f age, type of cardiac disease, heart failure severity, and
rug therapy. Right bundle branch block (RBBB) was not
ssociated with increased mortality (8).
Hesse et al. (9) evaluated 7,073 patients referred for
uclear exercise testing excluding those with heart failure or
acemakers. After adjustment for confounders, RBBB (HR
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Section of Cardiac Electrophysiology, University of Iowa Hospitals,
owa City, Iowa. Dr. Olshansky is a consultant for Guidant, the Principal Investigator
or the Guidant INTRINSIC RV study, a speaker for Guidant, a speaker and ac
onsultant for Medtronic, a member of an events committee for Medtronic, and has
een involved with several clinical trials for Medtronic in the past..5, 95% CI 1.1 to 2.1, p 0.007) and LBBB (HR 1.5, 95%
I 1.0 to 2.0, p  0.017) predicted mortality strongly.
EATH IN PATIENTS WITH A WIDE QRS
elayed ventricular activation manifested as a wide QRS is
ssociated with poorer outcomes in patients with or without
oronary artery disease. Abnormal electrical activation, as-
ociated with depolarization and repolarization abnormali-
ies, sets the stage for re-entry and thus life-threatening
entricular arrhythmias. A direct electrophysiologic link
etween the QRS width, ventricular arrhythmias, and death
herefore may exist.
Alternatively, delayed electrical activation can impair
ontractility and ventricular function. This may affect out-
omes independent of cardiac arrhythmias, but the QRS
idth may simply reflect the presence of extensive myocar-
ial damage without any specific causal relationship (7). The
rognostic value of the QRS width may be more closely
ssociated with the extent of the heart disease, the left
entricular ejection fraction, or heart failure symptoms.
Ischemic cardiomyopathy patients with a LBBB may
ave a poorer outcome because they may receive suboptimal
herapy (10). These conclusions were based on outcomes of
9,585 patients with LBBB enrolled in the National Reg-
stry of Myocardial Infarction (June 1994 to March 1998).
he mortality difference of patients with LBBB and myo-
ardial infarction presenting without chest pain could be
xplained by undertreatment, particularly with lower use of
spirin and beta-blocker therapies. An ICD may not pro-
ide benefit depending on the purported mechanism of
eath.
RS DURATION MAY PREDICT ICD BENEFIT
he QRS width seems to predict outcomes in an ICD
opulation with coronary artery disease. In the Multicenter
utomatic Defibrillator Implant Trial II (MADIT II) (11),
atients with a QRS width 150 ms had the greatest
urvival benefit from ICDs, presumably because ICDs
rotected against fatal VT/VF events. Although not de-
igned to address this, or any specific subanalysis, the
ADIT II study (11) suggested that QRS width and
ender predicted outcomes independently after ICD im-
lantation. Complicating the issue was that outcomes based
n QRS width were dependant on the cut point. When
RS duration was dichotomized at 120 ms, there was no
eaningful difference in ICD efficacy. Ironically, men
chieve the greatest benefit from prophylactic ICD im-
lants, but this latter point, now consistent among recent
CD trials, is not addressed in any guideline (11–13).
Similar results were observed in patients with non-
schemic cardiomyopathy. The DEFibrillators In Non-
schemic Cardiomyopathy Treatment Evaluation (DEFI-
ITE) trial (13), showed that patients with non-ischemicardiomyopathy who had a QRS 120 ms seemed to
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Editorial Comment July 19, 2005:317–9enefit the most from best medical therapy and an ICD
ersus best medical therapy alone.
The Sudden Cardiac Death-Heart Failure (SCD-HeFT)
rial (12) showed that patients undergoing ICD implanta-
ion who had either ischemic or non-ischemic cardiomyop-
thy and heart failure symptoms but whose QRS widths
ere 120 ms had lower mortality versus placebo (HR
.67, CI 0.49 to 0.93). Those with QRS widths 120ms
id not achieve the same benefit from the ICD (HR 0.84,
I 0.62 to 1.14).
These three major trials seem to indicate that the QRS
idth predicts benefit from an ICD, but none of these
tudies were designed to address this issue specifically.
ased on these data, however, Nudell, a senior research
nalyst from Sanford C. Bernstein and Company, con-
luded that patients with a QRS 120 ms have up to a
our-fold absolute mortality benefit from the ICD com-
ared with patients with a QRS 120 ms. This type of
nformation is considered seriously by the CMS (14).
In a sicker population, the Comparison of Medical
herapy: Pacing and Defibrillation in Heart Failure
COMPANION) trial (15), a study of patients who all had
RS widths 120 ms and New York Heart Association
unctional class III and IV heart failure symptoms, showed
hat those with the widest QRS complexes (168 ms)
erived the greatest benefit from a bi-ventricular (resyn-
hronization) ICD.
The weakness of these trials, including the PainFREE
xII trial, is that these trials were not designed to address
he issue of QRS duration in an ICD population. If the
CD does have specific benefit in patients with wide QRS
omplexes, it is likely because it treats life-threatening
entricular arrhythmias.
OW CAN WE EXPLAIN BUXTON’S STUDY?
he Buxton et al. (3) study showed that patients with ICDs
ho have wider QRS complexes did not have any difference
n VT/VF outcomes (3). This report included a different
atient population than that in the prophylactic ICD trials
11–13). The left ventricular ejection fractions were higher
n this study than the others and ranged up to 0.40. Those
ith the least impaired ejection fractions may represent a
ower-risk group even if the QRS is wide. Buxton has
autioned us before not to rely on ejection fraction because
t may not be a robust indicator of ICD benefit (16). One
onders, then, what is?
Few patients in the Buxton et al. (3) study had an LBBB.
rguably, this is the highest-risk population of those with a
ide QRS complex. The study may be underpowered to
etect differences between groups (3). Of those with wide
RS complexes, a nonspecific intraventricular conduction
elay was the most common in Buxton’s report and, based
n prior data, all ventricular conduction delays are not the
ame. Even considering the small number of patients with
BBB in Buxton’s study, however, the episode density of tT was less with an LBBB. Certainly an LBBB does not
mpart a more benign prognosis.
Relationships between symptoms, ejection fraction, and
RS type may better predict outcomes in these patients. An
ssociation between bundle branch block, ejection fraction,
nd gender is not explored here (17). Some antitachycardia
acing therapies delivered in this study may have been for
onsustained non–life-threatening VT, and this may vary
y QRS width. The study could not determine this as well.
It is likely that the patients with a wide QRS width
nrolled in this trial (3) were a relatively lower risk group.
here is no mention of heart failure status, nor is any
pecific heart failure therapy described. It is likely that there
s a relationship between the QRS width, episodic ventric-
lar tachycardia, and sudden cardiac death as well as total
ardiac death, but this may not be apparent because patients
ho are at the highest risk with a bundle branch block may
ave instead received a biventricular (resynchronization)
CD. With no registry data presented, there is no way to
now how many patients received resynchronization ther-
py in lieu of a standard ICD.
Finally, it is known that survival with right ventricular
acing (causing an LBBB morphology) is even worse than
n LBBB (18). In Buxton’s report, 75% of patients had
ual-chamber ICDs so that patients with and without a
ide QRS complex may have been paced, developing a
ide-paced QRS, thus leveling the playing field between
atient groups.
Considering these issues, it is likely that these data do not
resent a fair comparison between patients with a narrow
nd a wide QRS width.
S THIS REALLY AN ISSUE NOW?
ased on careful and appropriate analyses, the CMS has
lready concluded that a much wider range of patients can
enefit from an ICD regardless of the QRS width (14).
estriction regarding QRS duration has been removed from
heir recommendations. The Buxton et al. (3) data confirm
hat patients with coronary artery disease who have a wide
r a narrow QRS complex can benefit from an ICD. The
rticle (3) addresses what now seems to be a non-issue, but
s this really true? Not only does this study raise further
cientific questions, but it inadvertently raises questions
bout how we practice medicine.
How much should we as physicians be influenced by
MS guidelines? What is the best approach for patients not
ligible for CMS? What about patients who do not live in
he U.S.? Although CMS guidelines may or may not
epresent a reasonable compilation of the present data, we
ust make proper recommendations to our patients regard-
ng the best approach regardless of reimbursement issues. It
s good to know that patients selected to undergo standard
CD implantation are not at the greater risk for ICD
herapies for VT or VF if a wide QRS complex is present
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July 19, 2005:317–9 Editorial Commentnd that another specific intervention, such as an antiar-
hythmic drug, is not needed.
HE BOTTOM LINE
he QRS duration predicts outcomes of patients at risk for
ardiac death but, alone, it is not a predictor of VT/VF
vents in patients undergoing standard ICD implantation.
riteria independent of QRS duration are now used to
etermine the appropriateness of ICD implantation in
atients with or without coronary artery disease. Those
atients with QRS complexes 120 ms who have severe
eart failure symptoms and impaired ventricular function
ill benefit from a resynchronization ICD. Based on emerg-
ng data, it is likely that the role of the ICD and resynchro-
ization devices will become clearer and that indications will
row.
eprint requests and correspondence: Dr. Brian Olshansky,
ardiac Electrophysiology, University of Iowa Hospitals, 4426A
CP, 200 Hawkins Drive, Iowa City, Iowa 52242. E-mail:
rian-olshansky@uiowa.edu.
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